Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis

• DOI: 10.1007/s12325-019-00929-2
• Publication Date: 2019-03-30T19:03:33Z
• Authors: Zhou Zhou; Yanni Fan; Darren Thomason; Wenxi Tang; Xinyue Liu; Zheng-Yi Zhou; Dendy Macaulay; Aryeh Fischer
• Keywords: McNemar's test

Interstitial lung disease (ILD) is a common manifestation of scleroderma/systemic sclerosis (SSc). However, the direct and indirect economic burdens SSc-ILD remain unclear. This study assessed compared healthcare resource utilization (HRU), costs, work loss, costs between patients with matched controls neither SSc nor ILD in USA. Data were obtained from large US commercial claims database (2005–2015). Patients (at least 18 years old) had at one diagnosis inpatient (IP) or emergency room (ER) setting two diagnoses another setting, IP ER setting. Controls 5:1 to SSc-ILD. Comparisons conducted using Wilcoxon signed-rank McNemar's tests adjusted odds ratios (ORs) incidence rate (IRRs). A total 479 2395 included (52 260 for loss cost analyses). significantly higher HRU admissions (adjusted IRR = 5.6), hospitalization days 12.0), visits 2.8), OP 3.1), 4.5). The difference annual was $28,632 (SSc-ILD, $33,195; controls, $4562) that $4735 $5640; $906) (all p < 0.0001). HRU, ILD. Boehringer Ingelheim Pharmaceuticals, Inc.